Eltrombopag (Revolade®) + standard therapy (without eltrombopag): HD-DXM
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Immune Thrombocytopenia (ITP)
Conditions
Primary Immune Thrombocytopenia (ITP)
Trial Timeline
Sep 1, 2022 → Apr 11, 2024
NCT ID
NCT04812483About Eltrombopag (Revolade®) + standard therapy (without eltrombopag): HD-DXM
Eltrombopag (Revolade®) + standard therapy (without eltrombopag): HD-DXM is a phase 2 stage product being developed by Novartis for Primary Immune Thrombocytopenia (ITP). The current trial status is completed. This product is registered under clinical trial identifier NCT04812483. Target conditions include Primary Immune Thrombocytopenia (ITP).
What happened to similar drugs?
20 of 20 similar drugs in Primary Immune Thrombocytopenia (ITP) were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04812483 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Immune Thrombocytopenia (ITP)